110 related articles for article (PubMed ID: 21782)
1. The pharmacologic disposition of 4'-(9-acridinylamino)methanesulfon-m-anisidide in mice and rats.
Cysyk RL; Shoemaker D; Adamson RH
Drug Metab Dispos; 1977; 5(6):579-90. PubMed ID: 21782
[TBL] [Abstract][Full Text] [Related]
2. Identification of the principal biliary metabolite of 4'-(9-acridinylamino)methanesulfon-m-anisidide in rats.
Shoemaker DD; Cysyk RL; Padmanabhan S; Bhat HB; Malspeis L
Drug Metab Dispos; 1982; 10(1):35-9. PubMed ID: 6124380
[TBL] [Abstract][Full Text] [Related]
3. Oral absorption and selective tissue localization of 4'-(9-acridinylamino)-methanesulfon-m-anisidide.
Cysyk RL; Shoemaker DD; Ayers OC; Adamson RH
Pharmacology; 1978; 16(4):206-13. PubMed ID: 204947
[TBL] [Abstract][Full Text] [Related]
4. Phase I clinical and pharmacological study of 4'-(9-acridinylamino)-methanesulfon-m-anisidide using an intermittent biweekly schedule.
Van Echo DA; Chiuten DF; Gormley PE; Lichtenfeld JL; Scoltock M; Wiernik PH
Cancer Res; 1979 Oct; 39(10):3881-4. PubMed ID: 476624
[TBL] [Abstract][Full Text] [Related]
5. Interaction of 4'-(9-acridinylamino)methanesulfon-m-anisidide with DNA and inhibition of oncornavirus reverse transcriptase and cellular nucleic acid polymerases.
Gormley PE; Sethi VS; Cysyk RL
Cancer Res; 1978 May; 38(5):1300-6. PubMed ID: 76512
[TBL] [Abstract][Full Text] [Related]
6. Identification of conjugation and cleavage products in the thiolytic metabolism of the anticancer drug 4'-(9-acridinylamino)methanesulfon-m-anisidide.
Przybylski M; Cysyk RL; Shoemaker D; Adamson RH
Biomed Mass Spectrom; 1981 Oct; 8(10):485-91. PubMed ID: 6895335
[TBL] [Abstract][Full Text] [Related]
7. Studies on the metabolism and disposition of the new retinoid 4-[(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthyl)carbamoyl] benzoic acid. 4th communication: absorption, metabolism, excretion and plasma protein binding in various animals and man.
Mizojiri K; Okabe H; Sugeno K; Misaki A; Ito M; Kominami G; Esumi Y; Takaichi M; Harada T; Seki H; Inaba A
Arzneimittelforschung; 1997 Mar; 47(3):259-69. PubMed ID: 9105544
[TBL] [Abstract][Full Text] [Related]
8. Metabolism of 4'-(9-acridinylamino)methanesulfon-m-anisidide by rat liver microsomes.
Shoemaker DD; Cysyk RL; Gormley PE; DeSouza JJ; Malspeis L
Cancer Res; 1984 May; 44(5):1939-45. PubMed ID: 6546898
[TBL] [Abstract][Full Text] [Related]
9. Selective localization of 4'-(9-acridinylamino)-methanesulfon-m-anisidide in B 16 melanoma.
Shoemaker DD; Legha SS; Cysyk RL
Pharmacology; 1978; 16(4):221-5. PubMed ID: 204948
[TBL] [Abstract][Full Text] [Related]
10. NTP Toxicology and Carcinogenesis Studies of 1-Amino-2,4-Dibromoanthraquinone (CAS No. 81-49-2) in F344/N Rats and B6C3F1 Mice (Feed Studies).
National Toxicology Program
Natl Toxicol Program Tech Rep Ser; 1996 Aug; 383():1-370. PubMed ID: 12692653
[TBL] [Abstract][Full Text] [Related]
11. Comparison of DNA-protein cross-links induced by 4'-(9-acridinylamino)-methanesulfon-m-anisidide and by gamma-radiation.
Chiu SM; Xue LY; Friedman LR; Oleinick NL
Cancer Res; 1989 Feb; 49(4):910-4. PubMed ID: 2912561
[TBL] [Abstract][Full Text] [Related]
12. Phase I evaluation of 4'-(9-acridinylamino)methanesulfon-m-anisidide (AMSA) by a weekly iv dose schedule.
Woodcock TM; Schneider RJ; Young CW
Cancer Treat Rep; 1980 Jan; 64(1):53-5. PubMed ID: 6892893
[TBL] [Abstract][Full Text] [Related]
13. A fluorescence assay for 4'-(9-acridinylamino)methanesulfon-m-anisidide, a new antitumor agent.
Gormley PE; Cysyk RL
Anal Biochem; 1979 Jul; 96(2):504-7. PubMed ID: 112879
[No Abstract] [Full Text] [Related]
14. Topoisomerase II-mediated DNA damage produced by 4'-(9-acridinylamino)methanesulfon-m-anisidide and related acridines in L1210 cells and isolated nuclei: relation to cytotoxicity.
Covey JM; Kohn KW; Kerrigan D; Tilchen EJ; Pommier Y
Cancer Res; 1988 Feb; 48(4):860-5. PubMed ID: 2827887
[TBL] [Abstract][Full Text] [Related]
15. Human pharmacokinetics of a new acridine derivative, 4'-(9-acridinylamino)methanesulfon-m-anisidide (NSC 249992).
Hall SW; Friedman J; Legha SS; Benjamin RS; Gutterman JU; Loo TL
Cancer Res; 1983 Jul; 43(7):3422-6. PubMed ID: 6687834
[TBL] [Abstract][Full Text] [Related]
16. Metabolism of labetalol by animals and man.
Martin LE; Hopkins R; Bland R
Br J Clin Pharmacol; 1976 Aug; 3(4 Suppl 3):695-710. PubMed ID: 990152
[TBL] [Abstract][Full Text] [Related]
17. Toxicity of 4'-(9-acridinylamino)methanesulfon-m-anisidide in exponential- and plateau-phase Chinese hamster cell cultures.
Wilson WR; Giesbrecht JL; Hill RP; Whitmore GF
Cancer Res; 1981 Jul; 41(7):2809-16. PubMed ID: 6894713
[TBL] [Abstract][Full Text] [Related]
18. Metabolism and excretion of a novel antianxiety drug candidate, CP-93,393, in Long Evans rats. Differentiation of regioisomeric glucuronides by LC/MS/MS.
Prakash C; Soliman V
Drug Metab Dispos; 1997 Nov; 25(11):1288-97. PubMed ID: 9351906
[TBL] [Abstract][Full Text] [Related]
19. Pharmacokinetics and disposition of L-692,429. A novel nonpeptidyl growth hormone secretagogue in preclinical species.
Leung KH; Cohn DA; Miller RR; Doss GA; Stearns RA; Simpson RE; Feeney WP; Chiu SH
Drug Metab Dispos; 1996 Jul; 24(7):753-60. PubMed ID: 8818572
[TBL] [Abstract][Full Text] [Related]
20. Thiolytic cleavage of the anti-tumour compound 4'-(9-acridinylamino)-methanesulphon-m-anisidine (m-AMSA, NSC 156 303) in blood.
Wilson WB; Cain BF; Baguley BC
Chem Biol Interact; 1977 Aug; 18(2):163-78. PubMed ID: 890845
[No Abstract] [Full Text] [Related]
[Next] [New Search]
